IP Library › Granted Patent US 12,209,118
Granted Patent B2
US 12,209,118 · App. 17/625,715 · Granted Jan 28, 2025

Antibody compositions for disrupting biofilms

Inventors: Steven D. Goodman (Columbus, OH); Lauren O. Bakaletz (Columbus, OH)
Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
C07K16/1232A01N63/50A61P31/04C07K16/1018C07K16/12G01N33/56911A61K2039/505C07K2317/21C07K2317/24C07K2317/40C07K2317/41C07K2317/52C07K2317/54C07K2317/55C07K2317/565C07K2317/567C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,118
App. No.
17/625,715
Granted
Jan 28, 2025
Kind
B2
Abstract

Provided herein are methods and compositions for disrupting bio films in vitro and in vivo. Also disclosed are antibodies comprising a specified heavy chain (HC) immunoglobulin variable domain sequence and/or a specified light chain (LC) immunoglobulin variable domain sequence.

Claims (24)

1. An antibody or an antigen-binding fragment thereof comprising:

(i) a heavy chain complementarity-determining region 1 (CDRH1) comprising a sequence of GFTFSRY (aa 50 to aa 56 of SEQ ID NO: 4 or 5 or 6 or 26);

(ii) a heavy chain complementarity-determining region 2 (CDRH2) comprising a sequence of SSGGSY (aa 76 to aa 81 of SEQ ID NO: 4 or 5 or 6 or 26);

(iii) a heavy chain complementarity-determining region 3 (CDRH3) comprising a sequence of ER (aa 121 to aa 122 of SEQ ID NO: 4 or 5 or 6 or 26);

(iv) a light chain complementarity-determining region 1 (CDRL1) comprising a sequence of QDISNY (aa 47 to aa 52 of SEQ ID NO: 10 or 11 or 12 or 27);

(v) a light chain complementarity-determining region 2 (CDRL2) comprising a sequence of YTS (aa 70 to aa 72 of SEQ ID NO: 10 or 11 or 12 or 27); and

(vi) a light chain complementarity-determining region 3 (CDRL3) comprising a sequence of QQ (aa 109 to aa 110 of SEQ ID NO: 10 or 11 or 12 or 27).

2. An antigen-binding fragment thereof of the antibody of claim 1 .

3. The antigen-binding fragment thereof of claim 2 , wherein the antigen-binding fragment thereof is selected from the group of Fab, F(ab′) 2 , Fab′, scFv, or Fv.

4. An isolated polynucleotide encoding the antibody or the antigen-binding fragment thereof of claim 1 , and optionally operatively linked to a promoter and enhancer element.

5. A vector comprising an isolated polynucleotide of claim 4 .

6. A host cell comprising the polynucleotide of claim 4 .

7. A composition comprising a carrier and one or more of: an antibody or an antigen-binding fragment thereof of claim 1 , an isolated polynucleotide encoding the antibody or the antigen-binding fragment thereof, a vector comprising the isolated polynucleotide, or a host cell comprising the isolated polynucleotide.

8. A method of producing an antibody or an antigen-binding fragment thereof of claim 1 , comprising culturing a host cell comprising a polynucleotide encoding the antibody or the antigen-binding fragment thereof under conditions for expression of the antibody or the antigen-binding fragment thereof, and optionally isolating the antibody or the antigen-binding fragment thereof.

9. A method to detect a biofilm in a subject, comprising administering to the subject an antibody or an antigen-binding fragment thereof of claim 1 , and detecting binding of the antibody or the antigen-binding fragment thereof to the biofilm.

10. A non-physiological surface coated with an antibody or an antigen-binding fragment thereof of claim 1 ; and optionally, wherein the surface is in an industrial setting.

11. A kit comprising one or more of: an antibody or an antigen-binding fragment thereof of claim 1 , a polynucleotide encoding the antibody or the antigen-binding fragment thereof, a vector comprising the polynucleotide, the host cell comprising the polynucleotide, or the composition comprising any one or more of: the antibody or the antigen-binding fragment thereof, the polynucleotide, the vector, or the host cell; and optionally instructions for use.

12. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody further comprises a constant region selected from the group of: an IgA constant region, an IgD constant region, an IgE constant region, an IgG constant region, or an IgM constant region.

13. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof is modified by a process selected from PEGylation, polysialyation, HESylation, or glycosylation.

14. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody is a monoclonal antibody.

15. The antibody or the antigen-binding fragment thereof of claim 1 , further comprising a detectable label.

16. A method of detecting a microbial infection that produces a biofilm in a subject comprising contacting an antibody or an antigen-binding fragment thereof of claim 1 with a biological sample isolated from the subject.

17. The method of claim 9 , wherein the antibody or the antigen-binding fragment thereof is detectably labeled.

18. The method of claim 16 , wherein the antibody or the antigen-binding fragment thereof is detectably labeled.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2022
From: GOODMAN, STEVEN D.; BAKALETZ, LAUREN O.
To: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 060416/0585 →
Continuity (3)
Provisional Application 62871457 · Jul 8, 2019
Provisional Application 63033109 · Jun 1, 2020
Related Publication 20220275064A1 · Sep 1, 2022
References Cited (75)
US 6663863B2 · Horvath et al. · 2003 [cited by applicant]
US 6696550B2 · Larosa et al. · 2004 [cited by applicant]
US 8999291B2 · Goodman et al. · 2015 [cited by applicant]
US 9745366B2 · Goodman et al. · 2017 [cited by applicant]
US 10233234B2 · Kauvar et al. · 2019 [cited by applicant]
US 10570193B2 · Kauvar et al. · 2020 [cited by applicant]
US 10940204B2 · Bakaletz et al. · 2021 [cited by applicant]
US 11104723B2 · Goodman et al. · 2021 [cited by applicant]
US 11248040B2 · Kauvar et al. · 2022 [cited by applicant]
US 20100291177A1 · Hermans et al. · 2010 [cited by applicant]
US 20110236306A1 · Goodman et al. · 2011 [cited by applicant]
US 20140287426A1 · Arnold et al. · 2014 [cited by applicant]
US 20150086542A1 · Goodman et al. · 2015 [cited by applicant]
US 20150086561A1 · Kauvar et al. · 2015 [cited by applicant]
US 20150166641A1 · Goodman et al. · 2015 [cited by applicant]
US 20150197558A1 · Kauvar et al. · 2015 [cited by applicant]
US 20150216971A1 · Rotolo et al. · 2015 [cited by applicant]
US 20150299298A1 · Kauvar et al. · 2015 [cited by applicant]
US 20160095316A1 · Goodman et al. · 2016 [cited by applicant]
US 20160175440A1 · Goodman et al. · 2016 [cited by applicant]
US 20160194384A1 · Goodman et al. · 2016 [cited by applicant]
US 20160237145A1 · Kauvar et al. · 2016 [cited by applicant]
US 20180303900A1 · Bakaletz et al. · 2018 [cited by applicant]
US 20190000971A1 · Bakaletz et al. · 2019 [cited by applicant]
US 20190040127A1 · Wadehra et al. · 2019 [cited by applicant]
US 20190055304A1 · Kauvar et al. · 2019 [cited by applicant]
US 20190337996A1 · Bakaletz et al. · 2019 [cited by applicant]
US 20190338018A1 · Bakaletz et al. · 2019 [cited by applicant]
US 20200002409A1 · Goodman et al. · 2020 [cited by applicant]
JP 2016521752A · 2016 [cited by applicant]
JP 2016538824A · 2016 [cited by applicant]
WO WO2005111066A2 · 2005 [cited by applicant]
WO WO2011123396A1 · 2011 [cited by applicant]
WO WO2012034090A1 · 2012 [cited by applicant]
WO WO2014201305A1 · 2014 [cited by applicant]
WO WO2015048484A2 · 2015 [cited by applicant]
WO WO2015089502A2 · 2015 [cited by applicant]
WO WO2016154491A1 · 2016 [cited by applicant]
WO WO2017023863A1 · 2017 [cited by applicant]
WO WO2017192594A1 · 2017 [cited by applicant]
WO WO2018042385A2 · 2018 [cited by applicant]
WO WO2018129078A1 · 2018 [cited by applicant]
WO WO2019112978A2 · 2019 [cited by applicant]
WO WO2021007260A2 · 2021 [cited by applicant]
U.S. Appl. No. 16/746,708, filed Jan. 17, 2020, Trellis Bioscience, Llc. [cited by applicant]
U.S. Appl. No. 17/150,731, filed Jan. 15, 2021, the Research Institute at Nationwide Children's Hospital. [cited by applicant]
Bakaletz et al., “New strategies to target bacterial biofilms”, 28th Annual North American Cystic Fibrosis Conference (NACFC), Atlanta, GA, Oct. 9-11, 2014 (presentation), 2 pages. [cited by applicant]
Bendig, Mary M., “Humanization of Rodent Monoclonal Antibodies by CDR Grafting”, Methods: A Companion to Methods in Enzymology, 1995, vol. 8, pp. 83-93. [cited by applicant]
Brockson et al., “Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms,” Molecular Microbiology, vol. 93, No. 6, Aug. 19, 2014, pp. 1246-1258, Supp… [cited by applicant]
Brockson et al., “Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms,” Molecular Microbiology, vol. 93, No. 6, Aug. 19, 2014, pp. 1246-1258. [cited by applicant]
Brown et al., “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VHCDR2”, J. Immunol. May 1996, 155(9):3285-3291. [cited by applicant]
Busby, et al., “Systematic comparison of monoclonal versus polyclonal antibodies for mapping histone modifications by ChIP-seq”, bioRxiv preprint posted Oct. 17, 2016, 51 pages. [cited by applicant]
Chen, et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations”, The EMBO Journal, 1995, vol. 14, No. 12, pp. 2784-2794. [cited by applicant]
Estelles et al., “A High-Affinity Native Human Antibody Disrupts Biofilm from [cited by applicant]
Estrela et al., “Combining Biofilm-Controlling Compounds and Antibiotics as a Promising New Way to Control Biofilm Infections,” Pharmaceuticals, vol. 3, May 11, 2010, pp. 1374-1393. [cited by applicant]
Goodman et al., “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins,” Mucosal Immunology, vol. 4, No. 6, Nov. 2011, pp. 625-637. [cited by applicant]
Goodman S D et al., “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins”, Mucosal Immuno, Nature Publishing Group, vol. 4, No. 6, Nov. 1, 2011, pp. 625-6… [cited by applicant]
Goodman, “Making and breaking biofilms”, Ohio Branch American Society for Microbiology Annual Meeting, Columbus, OH, Apr. 11-12, 2014 (presentation), 12 pages. [cited by applicant]
Goodman, “The DNABII family of proteins: Diagnostic markers and therapeutic targets of bacterial biofilms”, International Congress on Bacteriology and Infectious Disease, Baltimore, MD, Nov. 21, 2013, 7 pages. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US2020/041082 dated Jan. 21, 2021, 13 pages. [cited by applicant]
Janeway, et al., “Immunobiology—The Immune System in Health and Disease,” Third Edition, 1997, Garland Publish Inc., 14 pages. [cited by applicant]
Kussie, et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity”, Journal of Immunology, 1994, vol. 152, pp. 146-152. [cited by applicant]
Laura A. Novotny et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo”, EBIOMEDICINE, vol. 10, Aug. 1, 2016, pp. 33-44. [cited by applicant]
Lipman, et al., “Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources”, ILAR Journal, 2005, pp. 258-268. [cited by applicant]
M. Elizabeth Brockson et al., “Evaluation of the kinetics and mechanism of action anti-integration host factor-mediated disruption of bacterial biofilms: Anti-IHF-mediated biofilm collapse”, Molecular Microbiology., Aug… [cited by applicant]
Malhotra et al., “Defining the functional epitopes of Integration Host Factor (IHF) to develop a novel biofilm-focused immunotherapeutic against nontypeable Haemophilus influenzae-induced chronic and recurrent otitis me… [cited by applicant]
Malhotra et al., “Fine mapping the functional epitopes within integration host factor, a novel therapeutic target for nontypeable Haemophilus influenza-induced diseases of the respiratory tract”, Abst. 12th Annual AMA R… [cited by applicant]
Notice of Allowance dated Jul. 14, 2021, from U.S. Appl. No. 17/161,588. [cited by applicant]
Novotny et al., “Antibodies against the majority subunit of Type 1V pili disperse nontypeable Haemophilus influenza biofilms in a LuxS-dependent manner and confer therapeutics resolution of experimental otitis media,” M… [cited by applicant]
Novotny et al., “Structural Stability of Burkholderia cenocepacia Biofilms Is Reliant on eDNA Structure and Presence of a Bacterial Nucleic Acid Binding Protein,” Plos One, vol. 8, No. 6, e67629, Jun. 2013, 15 pages. [cited by applicant]
Novotny, “Development of a novel biofilm-focused immunotherapeutic against NTHI-induced otitis media”, 18th International Symposium on Recent Advances in Otitis Media, National Harbor, MD, Jun. 7-11, 2015 (presentation)… [cited by applicant]
Novotny, et al., “Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization”, Vaccine 31, Jul.… [cited by applicant]
Novotny, et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo,” 2016, EBioMedicine 10:33-44. [cited by applicant]
Novotny, et al., “Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae”, Mucosal Immunol vol. 5 No. 1, Jul. 2011, pp… [cited by applicant]
Vajdos et al. “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis”, J Mol. Biol., Jul. 5, 2002, 320(2), pp. 415-428. [cited by applicant]